Literature DB >> 27721371

GvHD-free, relapse-free survival after reduced-intensity allogeneic hematopoietic cell transplantation in older patients with myeloid malignancies.

A Nazha1, L Rybicki1, D Abounader1, B Bolwell1, R Dean1, A T Gerds1, D Jagadeesh1, B K Hamilton1, B T Hill1, M Kalaycio1, H Liu1, B Pohlman1, R Sobecks1, M A Sekeres1, N S Majhail1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27721371     DOI： 10.1038/bmt.2016.254

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  9 in total

Review 1.  Measurement and impact of comorbidity in older cancer patients.

Authors:  M Extermann
Journal:  Crit Rev Oncol Hematol       Date:  2000-09       Impact factor: 6.312

Review 2.  How we approach patient evaluation for hematopoietic stem cell transplantation.

Authors:  M Hamadani; M Craig; F T Awan; S M Devine
Journal:  Bone Marrow Transplant       Date:  2010-05-17       Impact factor: 5.483

3.  Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT.

Authors:  Mohamed L Sorror; Michael B Maris; Rainer Storb; Frederic Baron; Brenda M Sandmaier; David G Maloney; Barry Storer
Journal:  Blood       Date:  2005-06-30       Impact factor: 22.113

Review 4.  Reduced intensity conditioning allogeneic hematopoietic cell transplantation for adult acute myeloid leukemia in complete remission - a review from the Acute Leukemia Working Party of the EBMT.

Authors:  Salyka Sengsayadeth; Bipin N Savani; Didier Blaise; Florent Malard; Arnon Nagler; Mohamad Mohty
Journal:  Haematologica       Date:  2015-07       Impact factor: 9.941

Review 5.  Who benefits from allogeneic transplantation for myelodysplastic syndromes?: new insights.

Authors:  Uwe Platzbecker
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2013

6.  A comparative assessment of the curative potential of reduced intensity allografts in acute myeloid leukaemia.

Authors:  N H Russell; L Kjeldsen; C Craddock; A Pagliuca; J A Yin; R E Clark; A Howman; R K Hills; A K Burnett
Journal:  Leukemia       Date:  2014-11-07       Impact factor: 11.528

7.  Composite end point of graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic cell transplantation.

Authors:  Shernan G Holtan; Todd E DeFor; Aleksandr Lazaryan; Nelli Bejanyan; Mukta Arora; Claudio G Brunstein; Bruce R Blazar; Margaret L MacMillan; Daniel J Weisdorf
Journal:  Blood       Date:  2015-01-15       Impact factor: 22.113

8.  Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: influence of pretransplantation comorbidities.

Authors:  Mohamed L Sorror; Michael B Maris; Barry Storer; Brenda M Sandmaier; Razvan Diaconescu; Christopher Flowers; David G Maloney; Rainer Storb
Journal:  Blood       Date:  2004-04-27       Impact factor: 22.113

Review 9.  The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes.

Authors:  James W Vardiman; Jüergen Thiele; Daniel A Arber; Richard D Brunning; Michael J Borowitz; Anna Porwit; Nancy Lee Harris; Michelle M Le Beau; Eva Hellström-Lindberg; Ayalew Tefferi; Clara D Bloomfield
Journal:  Blood       Date:  2009-04-08       Impact factor: 22.113
  9 in total
  3 in total

1.  Impact of Toxicity on Survival for Older Adult Patients after CD34+ Selected Allogeneic Hematopoietic Stem Cell Transplantation.

Authors:  Gunjan L Shah; Michael Scordo; Satyajit Kosuri; Diego Adrianzen Herrera; Christina Cho; Sean M Devlin; Taylor Borrill; Dean C Carlow; Scott T Avecilla; Richard C Meagher; Richard J O'Reilly; Ann A Jakubowski; Esperanza B Papadopoulos; Guenther Koehne; Boglarka Gyurkocza; Hugo Castro-Malaspina; Brian C Shaffer; Miguel-Angel Perales; Sergio A Giralt; Roni Tamari
Journal:  Biol Blood Marrow Transplant       Date:  2017-09-22       Impact factor: 5.742

Review 2.  Sex-Specific Cardiovascular Risks of Cancer and Its Therapies.

Authors:  Nicholas S Wilcox; Seth J Rotz; McKay Mullen; Evelyn J Song; Betty Ky Hamilton; Javid Moslehi; Saro H Armenian; Joseph C Wu; June-Wha Rhee; Bonnie Ky
Journal:  Circ Res       Date:  2022-02-17       Impact factor: 17.367

3.  Can Graft vs. Leukemia Effect Be Uncoupled From Graft vs. Host Disease? An Examination of Proportions.

Authors:  Elizabeth Krieger; Amir Ahmed Toor
Journal:  Front Immunol       Date:  2020-04-28       Impact factor: 7.561
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.